← All trials
NCT04605588
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 2, 2020
- Primary completion
- Apr 30, 2021
- Completion date
- Apr 30, 2021
- First posted
- Oct 28, 2020
- Last posted
- Dec 7, 2020
- Enrollment
- 70
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Rutgers UniversityLead sponsor
- Rutgers UniversityReponsible party - principal investigator
- Rutgers UniversityOverall official - principal investigator
- SynaVirCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.